Aclaris Therapeutics

Aclaris Therapeutics Announces Preliminary Topline Data from Trial of Oral ATI-450

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced positive preliminary topline results from a 12-week, Phase …

Aclaris Therapeutics Announces Preliminary Topline Data from Trial of Oral ATI-450 Read More